Stock PGNY PROGYNY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Progyny, Inc.

Equities

PGNY

US74340E1038

Managed Healthcare

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
32.04 USD -1.42% Intraday chart for Progyny, Inc. -2.02% -13.82%
Mar. 12 Transcript : Progyny, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Mar. 05 Progyny Insider Sold Shares Worth $403,260, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,307 3,672 4,553 2,893 3,563 3,079 - -
Enterprise Value (EV) 1 2,227 3,672 4,434 2,773 3,563 2,816 2,598 2,327
P/E ratio -67 x 90.2 x 76.3 x 104 x 60 x 46.9 x 31.7 x 27.5 x
Yield - - - - - - - -
Capitalization / Revenue 10 x 10.6 x 9.1 x 3.68 x 3.27 x 2.37 x 1.97 x 1.65 x
EV / Revenue 9.69 x 10.6 x 8.86 x 3.52 x 3.27 x 2.17 x 1.66 x 1.24 x
EV / EBITDA 121 x 113 x 65.8 x 22.1 x 19 x 12.4 x 9.36 x 6.95 x
EV / FCF -496 x 104 x 185 x 35.9 x - 16.3 x 11.8 x 8.3 x
FCF Yield -0.2% 0.96% 0.54% 2.78% - 6.12% 8.45% 12.1%
Price to Book 20.2 x - 18.2 x 8.26 x - 4.4 x 3.41 x 2.7 x
Nbr of stocks (in thousands) 84,046 86,634 90,430 92,883 95,836 96,110 - -
Reference price 2 27.45 42.39 50.35 31.15 37.18 32.04 32.04 32.04
Announcement Date 3/5/20 2/24/21 2/28/22 2/27/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 229.7 344.9 500.6 786.9 1,089 1,299 1,565 1,872
EBITDA 1 18.34 32.39 67.35 125.7 187.1 227.1 277.6 334.6
EBIT 1 16.21 8.348 32.34 23.34 62.18 223.8 275.5 339.1
Operating Margin 7.06% 2.42% 6.46% 2.97% 5.71% 17.23% 17.6% 18.12%
Earnings before Tax (EBT) 1 - 8.679 32.44 24.44 70.69 95.58 141.8 170.6
Net income 1 -8.569 46.46 65.77 30.36 62.04 70.32 104.5 126.7
Net margin -3.73% 13.47% 13.14% 3.86% 5.7% 5.41% 6.68% 6.77%
EPS 2 -0.4100 0.4700 0.6600 0.3000 0.6200 0.6828 1.012 1.167
Free Cash Flow 1 -4.49 35.17 23.91 77.15 - 172.3 219.6 280.4
FCF margin -1.95% 10.2% 4.78% 9.8% - 13.27% 14.03% 14.98%
FCF Conversion (EBITDA) - 108.56% 35.5% 61.38% - 75.89% 79.08% 83.81%
FCF Conversion (Net income) - 75.69% 36.35% 254.15% - 245.08% 210.09% 221.37%
Dividend per Share 2 - - - - - - - -
Announcement Date 3/5/20 2/24/21 2/28/22 2/27/23 2/27/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 122.3 127.6 172.2 195 205.4 214.3 258.4 279.4 280.9 269.9 289.1 334.8 339.9 333.6 365
EBITDA 1 16.48 15.14 24.81 32.88 34.96 33.05 46.36 47.46 50.02 43.23 49.6 58.97 61.61 56.28 65.01
EBIT 1 9.065 -0.188 -0.058 8.838 11.26 3.306 45.82 46.94 49.44 13.8 48.91 59.05 61.03 54.85 64.14
Operating Margin 7.41% -0.15% -0.03% 4.53% 5.48% 1.54% 17.73% 16.8% 17.6% 5.11% 16.92% 17.64% 17.96% 16.44% 17.57%
Earnings before Tax (EBT) 1 9.117 -0.398 -0.142 8.903 11.54 4.141 16.33 17.17 20.93 16.26 17.44 25.29 27.99 24.26 32.41
Net income 1 16.8 15.08 4.971 8.768 13.21 3.408 17.68 14.99 15.9 13.47 12.97 18.78 21 17.75 24.7
Net margin 13.74% 11.82% 2.89% 4.5% 6.43% 1.59% 6.84% 5.37% 5.66% 4.99% 4.49% 5.61% 6.18% 5.32% 6.77%
EPS 2 0.1700 0.1500 0.0500 0.0900 0.1300 0.0300 0.1800 0.1500 0.1600 0.1300 0.1265 0.1844 0.2021 0.1722 0.2400
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/28/22 5/5/22 8/5/22 11/3/22 2/27/23 5/8/23 8/3/23 11/7/23 2/27/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 80.4 - 119 120 - 263 481 752
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -4.49 35.2 23.9 77.2 - 172 220 280
ROE (net income / shareholders' equity) - 12.7% 31.4% 9.66% - 17.5% 21.7% 20%
ROA (Net income/ Total Assets) 10% - 21.5% 29.1% - 18.2% 16.8% 15.8%
Assets 1 -85.52 - 306 104.3 - 386.9 623.1 802.2
Book Value Per Share 2 1.360 - 2.760 3.770 - 7.280 9.400 11.90
Cash Flow per Share 2 -0.0700 0.3700 0.2600 0.8000 - 1.850 2.150 -
Capex 1 2.96 - 2.13 3.24 - 3.3 4.1 5.3
Capex / Sales 1.29% - 0.43% 0.41% - 0.25% 0.26% 0.28%
Announcement Date 3/5/20 2/24/21 2/28/22 2/27/23 2/27/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Progyny, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
32.04 USD
Average target price
46.9 USD
Spread / Average Target
+46.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Managed Healthcare

1st Jan change Capi.
PROGYNY, INC. Stock Progyny, Inc.
-13.82% 3.08B
ELEVANCE HEALTH, INC. Stock Elevance Health, Inc.
+13.93% 125B
CIGNA Stock Cigna
+18.37% 101B
CENTENE CORPORATION Stock Centene Corporation
-0.28% 39.69B
HUMANA INC. Stock Humana Inc.
-33.18% 36.86B
MOLINA HEALTHCARE, INC. Stock Molina Healthcare, Inc.
-5.28% 20.05B
ALIGNMENT HEALTHCARE, INC. Stock Alignment Healthcare, Inc.
-39.49% 993M
CLOVER HEALTH INVESTMENTS, CORP. Stock Clover Health Investments, Corp.
-28.58% 337M
Other Managed Healthcare
  1. Stock Market
  2. Equities
  3. PGNY Stock
  4. Financials Progyny, Inc.